These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 1442614

  • 21. Prolongation of the QT interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction.
    Todt H, Zojer N, Raberger G, Schütz W.
    Eur J Pharmacol; 1994 Nov 14; 265(1-2):43-52. PubMed ID: 7883028
    [Abstract] [Full Text] [Related]

  • 22. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.
    Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, Brendel J, Busch AE, Bleich M.
    Cardiovasc Res; 2003 Nov 01; 60(2):298-306. PubMed ID: 14613859
    [Abstract] [Full Text] [Related]

  • 23. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.
    Rousseau MF, Massart PE, van Eyll C, Etienne J, Ahn S, Ghadanfar M, Friedrich T, Pouleur H.
    Am J Cardiol; 2001 Jun 01; 87(11):1250-4. PubMed ID: 11377349
    [Abstract] [Full Text] [Related]

  • 24. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure.
    Brendorp B, Elming H, Jun L, Køber L, Torp-Pedersen C, DIAMOND Study Group. Danish Investigations Of Arrhythmia and Mortality On Dofetilide.
    Eur J Heart Fail; 2002 Mar 01; 4(2):201-6. PubMed ID: 11959050
    [Abstract] [Full Text] [Related]

  • 25. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias.
    Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, Friedrich T, Roden DM.
    J Cardiovasc Electrophysiol; 1995 Sep 01; 6(9):687-99. PubMed ID: 8556189
    [Abstract] [Full Text] [Related]

  • 26. Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker AZD1305 versus dofetilide in dogs with remodeled hearts.
    Johnson DM, de Jong MM, Crijns HJ, Carlsson LG, Volders PG.
    Circ Arrhythm Electrophysiol; 2012 Feb 01; 5(1):201-9. PubMed ID: 22080293
    [Abstract] [Full Text] [Related]

  • 27. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P, Dunnmon P, Elstun L, Newman D.
    J Cardiovasc Pharmacol Ther; 2002 Oct 01; 7(4):211-7. PubMed ID: 12490966
    [Abstract] [Full Text] [Related]

  • 28. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM, Ungab GA, Wadhwa M, Al-Kandari F, Yao B, Gupta A, Lee K, Kim HY, Feld GK.
    J Cardiovasc Pharmacol Ther; 2001 Jul 01; 6(3):297-306. PubMed ID: 11584336
    [Abstract] [Full Text] [Related]

  • 29. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan 01; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 30. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G, Xue X, Gao C, Huang J, Qi D, Zhang Y, Dong JZ, Ma CS, Yan GX.
    J Am Heart Assoc; 2017 May 18; 6(5):. PubMed ID: 28522677
    [Abstract] [Full Text] [Related]

  • 31. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide.
    Brendorp B, Elming H, Jun L, Køber L, Torp-Pedersen C, Diamond Study Group.
    Clin Cardiol; 2003 May 18; 26(5):219-25. PubMed ID: 12769249
    [Abstract] [Full Text] [Related]

  • 32. Comparison in the same patient of aberrant conduction and bundle branch reentry after dofetilide, a new selective class III antiarrhythmic agent.
    Crijns HJ, Kingma JH, Gosselink AT, Lie K.
    Pacing Clin Electrophysiol; 1993 May 18; 16(5 Pt 1):1006-16. PubMed ID: 7685880
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
    Chandra P, Rosen TS, Yeom ZH, Lee K, Kim HY, Danilo P, Rosen MR.
    Europace; 2004 Sep 18; 6(5):384-91. PubMed ID: 15294262
    [Abstract] [Full Text] [Related]

  • 34. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.
    Pedersen HS, Elming H, Seibaek M, Burchardt H, Brendorp B, Torp-Pedersen C, Køber L, DIAMOND Study Group.
    Am J Cardiol; 2007 Sep 01; 100(5):876-80. PubMed ID: 17719337
    [Abstract] [Full Text] [Related]

  • 35. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
    Merot J, Charpentier F, Poirier JM, Coutris G, Weissenburger J.
    Cardiovasc Res; 1999 Nov 01; 44(2):303-14. PubMed ID: 10690307
    [Abstract] [Full Text] [Related]

  • 36. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans.
    Tham TC, MacLennan BA, Burke MT, Harron DW.
    J Cardiovasc Pharmacol; 1993 Mar 01; 21(3):507-12. PubMed ID: 7681516
    [Abstract] [Full Text] [Related]

  • 37. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ.
    N Engl J Med; 1999 Sep 16; 341(12):857-65. PubMed ID: 10486417
    [Abstract] [Full Text] [Related]

  • 38. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN.
    Card Electrophysiol Rev; 2003 Sep 16; 7(3):225-8. PubMed ID: 14739718
    [Abstract] [Full Text] [Related]

  • 39. Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle.
    Yang T, Tande PM, Lathrop DA, Refsum H.
    Cardiovasc Drugs Ther; 1992 Aug 16; 6(4):429-36. PubMed ID: 1520650
    [Abstract] [Full Text] [Related]

  • 40. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle.
    Schmitt C, Brachmann J, Karch M, Waldecker B, Navarrete L, Montero M, Beyer T, Kübler W.
    Am J Cardiol; 1991 Nov 01; 68(11):1183-7. PubMed ID: 1951078
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.